Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment
Authors
Keywords
-
Journal
Biomarkers in Medicine
Volume 4, Issue 4, Pages 535-541
Publisher
Future Medicine Ltd
Online
2010-08-11
DOI
10.2217/bmm.10.74
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
- (2017) S. Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
- (2017) E. Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- (2010) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2010) Shirin Khambata-Ford et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- In Reply
- (2009) Jennifer W. Mack et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
- (2009) Marcello Tiseo et al. LUNG CANCER
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
- (2008) A Kalikaki et al. BRITISH JOURNAL OF CANCER
- Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
- (2008) Ludovic Barault et al. INTERNATIONAL JOURNAL OF CANCER
- Bleomycin in Testicular Cancer: Will Pharmacogenomics Improve Treatment Regimens?
- (2008) Carsten Bokemeyer JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors
- (2008) Z. Wu et al. PROSTATE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started